- Period of Performance Extended Through July 2023 at Prior Terms -
- Recognizes safeCircle’s™ Superior Integrated COVID-19 Testing and Vaccine Policy Management with Rapid Results Reporting and Campus Access Control -
- Mitigates Risk in the New Academic Year Given Surge in Variant Positivity Rates -
August 09, 2022. STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that The City University of New York (CUNY), the largest urban university in the United States, has extended its health services contract for COVID-19 testing and vaccine policy management with the Company’s wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), for 12 months through July 2023 and at the prior contract terms. ADCL’s COVID-19 testing volumes, including the CUNY contract, fueled the Company’s record fiscal 2021 revenues and consecutive quarterly record revenues in the first half of fiscal 2022 ended March 31, 2022.
“Given our infrastructure and client concentration in New York City, we are pleased to continue servicing CUNY while we expand our test offering and services.”
The contract has been successfully operational since August 2021. Through a partnership with CLEARED4 software platform, ADCL provides a wide range of COVID-19 related health services to help CUNY mitigate COVID-19 associated risks. These services, which are provided to CUNY’s 25 campuses and covering 300,000+ students, employees, auxiliary workers, contractors and visitors, include: (i) high-throughput RT-PCR COVID-19 testing (weekly testing and a robust randomized testing program); (ii) vaccination policy and documentation management; and, (iii) facility access control.
“We commend the CUNY Board of Trustees for taking a forward-thinking approach to ensure the continued health and safety of all CUNY stakeholders while remaining committed to the promise and value of in-person learning. As New York City grapples with a resurgence of infections fueled by the Omicron BA.5 subvariant that can potentially elude rapid test detection and more easily reinfect people, including those who have been vaccinated, boosted and/or previously infected, our ability to deliver rapid PCR-based results with actionable reporting and access management for safeCircle clients remains a standout,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “Given our infrastructure and client concentration in New York City, we are pleased to continue servicing CUNY while we expand our test offering and services.”
safeCircle is a fully integrated health testing platform that offers a customized suite of services to institutions and their personnel/members that encompasses: program design, RT-PCR and rapid antigen testing, sample kit distribution and collection, test site management, results reporting to individuals and program administrators, facilities access management, variant tracking, and vaccination documentation management.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.